tirzepatide phase 3 trial after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 SURMOUNT-3: Tirzepatide shows total mean

J.R.S., R.F., D.S.-B., and J.R.G

b Based on medical history

Concerns around misuse and market practices The commercialization of obesity drugs has also raised several concerns: Increasing availability without proper prescriptions Off-label use among individuals without clinical indications Marketing of these drugs as quick weight-loss solutions Entry of inadequately tested products positioned as supplements Such practices pose risks to patient safety and may undermine confidence in these therapies if adverse events increase

Patient assistance programs exist at both companies for eligible uninsured or underinsured patients

Current guidelines recommend at least 150 minutes per week of moderate aerobic activity (such as brisk walking) plus muscle-strengthening activities on 2 or more days per week

In the tirzepatide trial, participants lost an average of 6.9% of their weight after 12 weeks, while retatrutide participants lost 7.2% at the lowest dose after 24 weeks